Brand incubator Maesa is betting on the growing body care category with the launch of Ontu, a new line bringing high-performance, facial-inspired formulas to Target shelves at accessible price points, capitalizing on shifting consumer skincare rituals.
With pharmaceutical companies increasingly deploying AI in direct-to-consumer platforms, the regulatory landscape remains fragmented. In the absence of comprehensive federal action, states are stepping in with disparate laws to address privacy and safety concerns, creating a complex compliance challenge for the industry.
As the AI arms race intensifies, Broadcom (AVGO) is emerging as a formidable challenger to Nvidia's dominance, fueled by a surging custom chip business and a compelling growth narrative that's catching Wall Street's eye.
PepsiCo's CEO expands his tech governance role at IBM, while a new financial chief takes the helm in the critical India region. These moves come as the beverage and snack giant's stock shows resilience, prompting investor analysis of its future direction.
Lawmakers reconvene Monday as House GOP leadership pushes for rapid passage of a stopgap funding bill to prevent a prolonged partial government shutdown, with tensions high over border security provisions.
As YouTube emerges as a key AI training data source, Reddit navigates a complex web of challenges: protecting its community brands, defending ad revenue against TikTok and AI search, and proving the value of its data licensing strategy to investors.
Nvidia's landmark plan to invest up to $100 billion in OpenAI has stalled, with executives questioning the deal's structure and OpenAI's financial discipline amid a fiercely competitive AI landscape.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
A pervasive culture of silence around estate planning is setting the stage for confusion and conflict as trillions in assets prepare to change hands. Experts warn that avoiding 'the talk' is a disservice to both generations.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
As market leadership broadens beyond tech, income-focused investors are turning to high-yield dividend ETFs. Vanguard's suite offers diversified, cost-effective options for building retirement income streams in a changing landscape.
A new bilateral trade agreement between the United States and Guatemala aims to eliminate tariffs and streamline preferential treatment for textiles and apparel, a move hailed by U.S. industry leaders as a strategic step to reinforce regional manufacturing networks and counter Asian dominance.
For those on a fixed income, inflation isn't just an economic indicator—it's a direct assault on financial security. Experts warn that failing to plan for rising costs can halve a retiree's purchasing power over decades. Here’s a strategic guide to building a resilient portfolio.
Amid a mixed market backdrop, penny stocks are drawing renewed attention for their growth potential. We analyze three standout picks, led by financial services firm Siebert Financial, highlighting their financial health and strategic moves in a volatile landscape.
The Rafah border crossing, Gaza's sole gateway to Egypt, has partially reopened for pedestrian traffic after a prolonged Israeli closure, offering a fragile hope for medical evacuations and family reunifications.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
In the shadow of tech giants, two quantum computing specialists, IonQ and D-Wave Quantum, are vying for investor attention with distinct approaches to AI. While both remain speculative bets, a closer look at their technology, finances, and market position reveals one as a potentially less volatile choice for those venturing into this frontier.
Amid a choppy market landscape in early 2026, value investors are scanning for opportunities. We analyze three companies—Viavi Solutions, Kontoor Brands, and Robert Half—whose current share prices appear significantly disconnected from their estimated intrinsic worth based on cash flow projections.
A landmark investment proposal between AI titans Nvidia and OpenAI has stalled, with both companies reassessing terms amid internal concerns and a shifting competitive landscape, according to a Wall Street Journal report.
Millions rely on Medicare, yet common misunderstandings about its coverage rules and costs can lead to significant financial shocks in retirement. We clarify three critical areas where assumptions often prove wrong.
